In what it's calling its "best and final offer," Biogen Idec Inc. upped its bid for daclizumab partner Facet Biotech Corp. to $17.50 per share, which values the Redwood City, Calif.-based firm at about $438 million. (BioWorld Today) Read More
No AbstractRumors of another European initial public offering in the works - this one by Brussels, Belgium-based Movetis - proved true, and the cash raised fell nicely within the range of speculators: €85 million (US$126 million), through the sale of about 6.9 million shares at €12.25 each.About 1 million shares as an overallotment, equivalent to €12.75 million, are allocated, and if that option is exercised in full by underwriters, the money garnered by the IPO will increase to €97.75 million. Read More
